PMID- 3123558
OWN - NLM
STAT- MEDLINE
DCOM- 19880315
LR  - 20201214
IS  - 0022-202X (Print)
IS  - 0022-202X (Linking)
VI  - 90
IP  - 2
DP  - 1988 Feb
TI  - Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response.
PG  - 158-64
AB  - We have developed an enzyme-linked immunosorbent assay (ELISA) for autoantibody 
      to Ro/SS-A antigen (anti-Ro/SS-A) in order to more fully characterize the 
      autoimmune response that occurs to this antigen in patients with subacute 
      cutaneous lupus erythematosus (SCLE). The microtiter plate-immobilized, 
      biochemically purified Ro/SS-A antigen reacted with anti-Ro/SS-A antibody, but 
      not with other closely related specificities (anti-La/SS-B, anti-SM, anti-U1-RNP) 
      or normal sera. The optimal pH of antigen-antibody reaction in this ELISA was 
      7.2. The binding of sera containing anti-Ro/SS-A was inhibited 80% by 
      preincubation with the same amount of Ro/SS-A antigen used for coating the plate. 
      Although 11 of the 14 (79%) SCLE sera studied had precipitating anti-Ro/SS-A 
      antibody by immunodiffusion, 13 (93%) sera had abnormally elevated IgG, IgA, or 
      IgM ELISA binding levels. A good correlation between IgG anti-Ro/SS-A ELISA 
      binding levels and immunodiffusion titers was observed (r - 0.8588, p less than 
      or equal to 0.001) suggesting that IgG is the major anti-Ro/SS-A antibody class 
      detected by double immunodiffusion, Sera with a combination of high rheumatoid 
      factor levels (latex 3+ or higher) and high anti-Ro/SS-A titers (1:8 or higher in 
      immunodiffusion) tended to give an abnormally high IgM anti-Ro/SS-A ELISA binding 
      levels. After rheumatoid factor activity was removed by absorption with 
      heat-aggregated human IgG, a 50% decrease in IgM anti-Ro/SS-A ELISA binding was 
      noted. On the other hand, absorption of rheumatoid factor-negative sera that 
      contained high IgM anti-Ro/SS-A binding activity did not significantly decrease 
      ELISA binding levels. Prednisone and 6-azathioprine reduced the level of IgG 
      anti-Ro/SS-A autoantibody in sera of treated SCLE patients by 50%. The IgG 
      subclass profile of anti-Ro/SS-A autoantibody was analyzed by using mouse 
      monoclonal antibodies specific for the 4 human IgG subclasses. Of anti-Ro/SS-A 
      positive SCLE sera, 91% had predominantly IgG1 subclass autoantibody. The 
      coexistence of IgM and IgG anti-Ro/SS-A autoantibody and the predominance of the 
      IgG1 subclass is compatible with the possibility that this autoantibody response 
      is under T-cell control. The predominance of IgG1 in the autoimmune response to 
      Ro/SS-A antigen in SCLE patients is consistent with the hypothesis that antibody 
      dependent cell mediated cytotoxicity could be an important immunologic effector 
      mechanism in this disorder.
FAU - Lieu, T S
AU  - Lieu TS
AD  - Department of Dermatology, University of Texas Health Science Center, Dallas 
      75235.
FAU - Reimer, C B
AU  - Reimer CB
FAU - Sontheimer, R D
AU  - Sontheimer RD
LA  - eng
GR  - AM19101/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (RNA, Small Cytoplasmic)
RN  - 0 (RO60 protein, human)
RN  - 0 (Ribonucleoproteins)
RN  - 0 (SS-A antigen)
RN  - 9009-79-4 (Rheumatoid Factor)
SB  - IM
MH  - Animals
MH  - Autoantibodies/*analysis/classification
MH  - Autoantigens/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Immunodiffusion
MH  - Immunoglobulin G/*analysis/classification
MH  - Immunoglobulin M/*analysis/classification
MH  - Immunosuppressive Agents/pharmacology
MH  - Lupus Erythematosus, Cutaneous/immunology
MH  - Mice
MH  - *RNA, Small Cytoplasmic
MH  - Rheumatoid Factor/analysis
MH  - *Ribonucleoproteins
EDAT- 1988/02/01 00:00
MHDA- 1988/02/01 00:01
CRDT- 1988/02/01 00:00
PHST- 1988/02/01 00:00 [pubmed]
PHST- 1988/02/01 00:01 [medline]
PHST- 1988/02/01 00:00 [entrez]
AID - S0022-202X(88)91136-0 [pii]
AID - 10.1111/1523-1747.ep12462142 [doi]
PST - ppublish
SO  - J Invest Dermatol. 1988 Feb;90(2):158-64. doi: 10.1111/1523-1747.ep12462142.